The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in July and August 2019 concern various types of devices, including orthopedic, cardiovascular, and blood glucose meters. A total of 29 decisions were made.

In response to multiple requests from our clients, we have started the provision of service of health economic modeling for medical technologies and IVD tests in Europe. Both early and comprehensive models eligible for publication are supported.

We have released the second part of the interview on the Market Access Insider channel on Youtube. The interview covered key stakeholders, procedure coding, principles of functioning of DRG system and add-on reimbursement for medical devices via LPPR List. Reimbursement pathways for devices, evidence requirements, pricing considerations, innovation funding (PHRC, PRME, forfeit innovation, Article 51, ETAPES program) were also discussed.

The report presents a summary of the reimbursement situation for use of biologic and synthetic skin substitutes in Europe. The following clinical indications are considered: burns; chronic wounds (hypertrophic scar). The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

The report presents a summary of the reimbursement situation for treatment of burns in Europe. The following types of treatment for burns of are considered: debridement of burn skin; dressing of burnt skin (including vacuum assisted closure device); placement of split-thickness skin autograft. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

In mid-August 2019, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA22 “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin.”

Using its deep knowledge of market access pathways in Europe and a specific, fact-based, benchmarking approach, MTRC can support the development of reliable clinical and economic evidence generation strategy.

The Institute for Quality and Efficiency in Health Care (IQWiG) has presented its second final report on the benefit assessment of vacuum therapy in wounds healing. The previous final report for vacuum therapy in the wounds healing by secondary intention was published by IQWiG in late March 2019.

Using its deep expertise in payment systems in Europe, MTRC has started provision of service of cost analysis to inform the development of health economic models and adaptation of existing models to settings of 19 European countries.

In August 2019, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI-HTA) published four decision support documents. The assessed technologies are osteochondral allograft transplantation, allograft for anterior and posterior cruciate ligament reconstruction, human dermal allograft, and 177 Lutetium.

MTRC is expanding its service offering to pharma companies. The scope of the services includes reimbursement analysis and strategy for hospital (high cost) drugs, cell and gene therapies, companion diagnostics, drug delivery systems and e-health solutions.

In May and November each year, NHS England makes decisions on which new treatments should be included for routine commissioning. The decisions are taken by the NHS England Board based on recommendations from the Clinical Priorities Advisory Group (CPAG), which is made up of doctors, health experts, and patient representatives.